Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $6.08B
- Enterprise value
- $6.08B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $95.31
- 52-wk low
- $34.34
- Beta
- —
- Shares out
- 74.9M
5-year trend
What this company does
Item 1. Business Overview We are a clinical stage biotechnology company advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (“I&I”) markets, including for the treatment of atopic dermatitis (“AD”), asthma, eosinophilic esophagitis (“EoE”), chronic obstructive pulmonary disease (“COPD”), and other I&I indications. Our antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Our pipeline comprises multiple antibody programs being developed…
AI summary unavailable — showing raw filing excerpt
Generated from APGE's filing dated 2026-03-02
Key risks
Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should consider carefully the risks described below, together with the other information contained in this Annual Report, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited consolidated financial statements and related notes. We believe the risks described below are the risks that are material to us as of the date of this Annual Report. Some of the factors, events and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or…
AI summary unavailable — showing raw filing excerpt
Generated from APGE's filing dated 2026-03-02
Profitability
Return on assets
-27.3%
13.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-74.1M | -33.9% | — |
Q4 2025 2025-12-31 | — | — | $-69.4M | -3.2% | — |
Q3 2025 2025-09-30 | — | — | $-65.0M | -32.6% | — |
Q2 2025 2025-06-30 | — | — | $-66.1M | -95.5% | — |
Q1 2025 2025-03-31 | — | — | $-55.3M | -72.4% | — |
Q4 2024 2024-12-31 | — | — | $-67.2M | — | — |
Q3 2024 2024-09-30 | — | — | $-49.0M | -135.2% | — |
Q2 2024 2024-06-30 | — | — | $-33.8M | -79.1% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on APGE — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$15.0M
Insider selling
$154.6M
Net activity
−$139.6M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns APGE
Institutional value
$1.25B
Total shares held
15.0M
Distinct holders
108
-99 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4.1M | $343.9M | +301.7K (+8.0%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.5M | $210.6M | — | New |
| 3 | UBS Group AG | 1.1M | $96.3M | +169.5K (+17.4%) | Added |
| 4 | JPMORGAN CHASE & CO | 1.1M | $87.4M | -262.6K (-19.1%) | Trimmed |
| 5 | JENNISON ASSOCIATES LLC | 585.0K | $49.2M | +6.4K (+1.1%) | Added |
| 6 | Remedium Capital Partners, LLC | 583.6K | $49.1M | +0 (+0.0%) | No change |
| 7 | FEDERATED HERMES, INC. | 442.7K | $37.3M | +314.8K (+246.1%) | Added |
| 8 | FRANKLIN RESOURCES INC | 405.5K | $34.1M | -45.5K (-10.1%) | Trimmed |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 396.3K | $33.4M | — | New |
| 10 | VANGUARD FIDUCIARY TRUST CO | 369.0K | $31.1M | — | New |
| 11 | Capital World Investors | 348.7K | $29.3M | +221.1K (+173.2%) | Added |
| 12 | Pictet Asset Management Holding SA | 261.1K | $22.0M | -51.8K (-16.6%) | Trimmed |
| 13 | Candriam S.C.A. | 223.5K | $18.8M | -159.1K (-41.6%) | Trimmed |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 220.1K | $18.5M | +210.1K (+2108.7%) | Added |
| 15 | TD ASSET MANAGEMENT INC | 184.8K | $15.6M | +55.5K (+42.9%) | Added |
| 16 | abrdn plc | 143.4K | $12.1M | +107.3K (+297.1%) | Added |
| 17 | Nuveen, LLC | 128.1K | $10.8M | +7.1K (+5.8%) | Added |
| 18 | Universal- Beteiligungs- und Servicegesellschaft mbH | 128.0K | $10.8M | +386 (+0.3%) | Added |
| 19 | Bank of New York Mellon Corp | 126.8K | $10.7M | +8.7K (+7.3%) | Added |
| 20 | KENNEDY CAPITAL MANAGEMENT LLC | 122.7K | $10.3M | -2.3K (-1.8%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once APGE's latest filing finishes processing.